Dr. Ivette Hernandez, MD

Dr. Hernandez practices at Delray Beach Surgery Center in Delray Beach, Florida.

Dr. Hernandez's NPI, 1629066295, was assigned on October 7, 2005. Dr. Hernandez holds Florida license ME54314.

Dr. Hernandez's primary practice is Delray Beach Surgery Center, at 4800 Linton Blvd, Bldg B, Delray Beach, FL 33445. The practice phone is (561) 495-9111.

Dr. Hernandez's primary practice is Delray Beach Surgery Center in Delray Beach, Florida. The medical group on file is Personal Physician Care. Dmand AI also links Dr. Hernandez to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hernandez practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Hernandez's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Hernandez is licensed in Florida.

CMS data shows 99 Medicare services from Dr. Hernandez across 2 procedure codes in 2024, for 64 Medicare patients. Medicare paid $7,290 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 64 Medicare patients who saw Dr. Hernandez in 2024. The largest group is 85 and over, with 28 patients. 75% of them have arthritis, and 75% have depression. 61% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hernandez's median patient age at 73, with 53% women.

In 2024, Dr. Hernandez wrote 345 Medicare Part D claims for 191 patients. 92% of them were for generic drugs. CMS names the drug for 89 of them, across 5 drugs with 11 or more claims each, at $1,003 in total drug cost. In 2023, CMS named 308 claims across 18 drugs.

Dr. Hernandez accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 32 general payments to Dr. Hernandez from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $420.